Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

AL Amyloidosis Therapy and Targets in 2019: Bortezomib Remains Mainstay in Frontline, ASCT in Upfront Is Questionable, Targeted Therapies Offer Promise, IO to Be Proven

0 views
November 18, 2019
Comments 0
Login to view comments. Click here to Login